DRUGdiscontinuedsmall molecule
olesoxime
Mechanism
Mitochondrial function, cholesterol binding. Positive in SMND7 mice (2014). Both survival + motor function improved.. DISCONTINUED 2018 (Roche) — Phase 3 OLEOS failed futility analysis; development halted.
Related claims (16)
| Type | Predicate | Conf | Source |
|---|---|---|---|
| motor function | Olesoxime treatment was associated with changes from baseline in Motor Function Measure (MFM) Dimension 1 (D1) + Dimension 2 (D2) Score in patients with SMA (clinical trial result) | 65% | NCT02628743_results |
| neuroprotection | Numerous preclinical studies have successfully proved olesoxime's neuroprotective properties in cell and animal models of spinal muscular atrophy. | 59% | 31283931 |
| motor function | Secondary endpoints and sensitivity analyses suggest that olesoxime might maintain motor function in patients with type 2 or type 3 SMA over a period of 24 months (clinical trial result). | 59% | 28460889 |
| drug efficacy | Neuroprotective drugs as olesoxime or riluzole have shown positive effects in preclinical studies but no clear efficacy in clinical trials. | 53% | 28524214 |
| safety | Treatment with Olesoxime was associated with adverse events and serious adverse events in patients with SMA (clinical trial result) | 53% | NCT02628743_results |
| safety | Olesoxime seemed to be safe and generally well tolerated, with an adverse event profile similar to placebo (clinical trial result). | 53% | 28460889 |
| drug efficacy | Previous treatment with olesoxime in the Phase 2 study was not protective of motor function in OLEOS (clinical trial result). | 53% | 33246887 |
| drug efficacy | Olesoxime's efficacy and safety were assessed in a Phase 2 study using data from 110 individuals with Type 2 or 3 SMA. | 53% | 32946459 |
| drug efficacy | Olesoxime has shown some improvement in treating SMA. | 53% | 39514016 |
| motor function | Olesoxime treatment was associated with changes from baseline in MFM Total Score (D1+ D2 + Dimension 3 [D3]) Score in patients with SMA (clinical trial result) | 51% | NCT02628743_results |
| drug efficacy | Olesoxime at 10 mg/kg BID was evaluated for long-term safety, tolerability, and effectiveness in patients with Spinal Muscular Atrophy (clinical trial result) | 51% | NCT02628743_results |
| drug efficacy | Very low-certainty evidence suggested that olesoxime had little or no effect on motor function (clinical trial result) | 45% | 32006461 |
| drug efficacy | Olesoxime might help in the maintenance of motor function in patients with Types 2/3 SMA (clinical trial result). | 45% | 33246887 |
| drug efficacy | Olesoxime might provide meaningful clinical benefits for patients with SMA (clinical trial result). | 45% | 28460889 |
| drug target | Olesoxime has emerged as a promising drug candidate for neurodegenerative diseases. | 45% | 31283931 |
| drug efficacy | Olesoxime had little or no effect on motor function in SMA types II or III in comparison to placebo (clinical trial result, very low-certainty evidence). | 42% | PMID:32006461 |
Off-Target Findings (0)
No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.